The safety of long-acting ß2-agonists in the treatment of stable chronic obstructive pulmonary disease
about
sameAs
Long-acting inhaled therapy (beta-agonists, anticholinergics and steroids) for COPD: a network meta-analysisLong-acting inhaled therapy (beta-agonists, anticholinergics and steroids) for COPD: an overview and network meta-analysisLong-acting inhaled therapy (beta-agonists, anticholinergics and steroids) for COPD: a network meta-analysisOnce-daily fluticasone furoate/vilanterol 100/25 mcg versus twice daily combination therapies in COPD - mixed treatment comparisons of clinical efficacyCan the anti-inflammatory activities of β2-agonists be harnessed in the clinical setting?COPD: maximization of bronchodilation.One-year safety and efficacy study of arformoterol tartrate in patients with moderate to severe COPD.Diagnosis and pharmacotherapy of stable chronic obstructive pulmonary disease: the finnish guidelines.V0162 a new long-acting bronchodilator for treatment of chronic obstructive lung diseases: preclinical and clinical resultsInhaled Long-Acting β2-Agonists Do Not Increase Fatal Cardiovascular Adverse Events in COPD: A Meta-Analysis.Effect of indacaterol on lung deflation improves cardiac performance in hyperinflated COPD patients: an interventional, randomized, double-blind clinical trialEmergency Hospital Care for Exacerbation of COPD: Is Inhaled Maintenance Therapy Modified?Coronary artery disease concomitant with chronic obstructive pulmonary disease.Update on ultra-long-acting β agonists in chronic obstructive pulmonary disease.Review of drug safety and efficacy of arformoterol in chronic obstructive pulmonary disease.The relationship between perioperative administration of inhaled corticosteroid and postoperative respiratory complications after pulmonary resection for non-small-cell lung cancer in patients with chronic obstructive pulmonary disease.Efficacy, safety, and tolerability of once-daily abediterol in patients with stable, persistent asthma: a Phase II, randomized, 7-day, crossover study.Comprehensive assessment of the safety of olodaterol 5 µg in the Respimat® device for maintenance treatment of COPD: comparison with the long-acting β2-agonist formoterol.UGT1A1*28 is associated with greater decrease in serum K⁺ levels following oral intake of procaterol.Prevalence of undiagnosed COPD in male patients with coronary artery disease: a cross-sectional study in Jordan
P2860
Q24197853-F03A5715-264D-42F1-92B6-13BFDF242FADQ24197946-F725C26B-9192-4C76-B5C4-ADC337A323FBQ24202279-9386FE59-ADF4-42E5-83A0-6C92B876F73AQ27010444-E4F248E8-73BA-4530-9DD8-0148CCB62438Q28391808-6A3D3A37-0ED4-454F-8C03-C38E6AF0B4B9Q34436393-14DDA362-64B6-4277-8C5C-8196AD8FE8D9Q34609913-8DF93F9C-5BFD-4E47-A604-F21BCB3AC266Q35538249-5356E3CC-0CF5-4FA7-AFE3-36A55407D11FQ35710238-2CFA3E52-18BC-4261-8710-17EF432E8461Q35778149-8DDBDB71-8A10-4297-A01B-14DE3D6ECC75Q36072399-7BD9BA09-B541-4076-9537-AD7D8724C945Q36652471-90BBFC25-F94C-495D-96E7-590DDBD2AA80Q38155898-A1563537-5DDE-4567-893A-82F5CA8C293CQ38241442-BB39A3BC-059B-47E1-9303-067A26FFFD8BQ38308933-982EB278-01A5-481A-A37D-C40F33639770Q41290076-6EBEFDCF-0093-42F1-AD17-151A80D47FACQ42285690-FE8CE323-0CB6-45B5-9D18-B85B5725E35AQ42645176-7AAC9669-AA07-4306-A09E-4315C541016CQ51701030-9C45EF6E-8651-4754-A3B8-80E7164B52E1Q57312139-8B8C03F6-9651-42CB-981B-7F0F26901A37
P2860
The safety of long-acting ß2-agonists in the treatment of stable chronic obstructive pulmonary disease
description
2013 nî lūn-bûn
@nan
2013 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
name
The safety of long-acting ß2-a ...... obstructive pulmonary disease
@ast
The safety of long-acting ß2-a ...... obstructive pulmonary disease
@en
The safety of long-acting ß2-a ...... obstructive pulmonary disease
@en-gb
The safety of long-acting ß2-a ...... obstructive pulmonary disease
@nl
type
label
The safety of long-acting ß2-a ...... obstructive pulmonary disease
@ast
The safety of long-acting ß2-a ...... obstructive pulmonary disease
@en
The safety of long-acting ß2-a ...... obstructive pulmonary disease
@en-gb
The safety of long-acting ß2-a ...... obstructive pulmonary disease
@nl
altLabel
The safety of long-acting β2-a ...... obstructive pulmonary disease
@en
prefLabel
The safety of long-acting ß2-a ...... obstructive pulmonary disease
@ast
The safety of long-acting ß2-a ...... obstructive pulmonary disease
@en
The safety of long-acting ß2-a ...... obstructive pulmonary disease
@en-gb
The safety of long-acting ß2-a ...... obstructive pulmonary disease
@nl
P2093
P2860
P577
P356
P1476
The safety of long-acting ß2-a ...... obstructive pulmonary disease
@en
The safety of long-acting β2-a ...... obstructive pulmonary disease
@en
P2093
Barbara P Yawn
Barbara Yawn
Marc Decramer
Marc L Decramer
P2860
P356
10.2147/COPD.S39018
P407
P577
2013-01-01T00:00:00Z
2013-01-25T00:00:00Z